Compound as KIF18A inhibitor and application thereof
By developing a new KIF18A inhibitor, the toxicity problems and poor selective killing effects of existing tubulin inhibitors were solved, and effective treatment of diseases related to KIF18A was achieved.
CN119707925APending Publication Date: 2025-03-28NANJING SANHOME PHARM RES & DEV CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202411346216.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-27
- Filing Date
- 2024-09-26
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
Existing tubulin inhibitors, such as paclitaxel and vincristine, have neurotoxic and myelosuppressive toxicity, and have poor selective killing effects on tumor cells, making it difficult to effectively treat diseases related to KIF18A.
Method used
A new KIF18A inhibitor is developed to interact with KIF18A through specific compound structures, inhibiting its function, thereby inducing tumor cell apoptosis.
Benefits of technology
The KIF18A inhibitor shows good tumor cell specificity and low myelosuppression toxicity, which can effectively induce apoptosis of tumor cells containing aneuploid chromosomes, and has the potential to become a new tumor treatment method.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the field of medical chemistry, relates to a compound serving as a KIF18A inhibitor and application of the compound, and particularly provides a compound shown in a formula (I) or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of the compound, processes for their preparation, pharmaceutical compositions containing these compounds and the use of these compounds or compositions for the treatment of diseases associated with KIF18A. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art